Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Eur J Cancer. 2017 Sep 17;85:133–145. doi: 10.1016/j.ejca.2017.08.020

Fig. 2.

Fig. 2

Change in Ki67 levels and percentage of TILs. a: Change in Ki67 levels from baseline up to day 15 with buparlisib versus placebo. b: Change in percentage of TILs from baseline up to day 15 with buparlisib versus placebo. TIL, tumor infiltrating lymphocytes.